23rd Sep 2026 07:00
Novacyt S.A.
(“Novacyt”, the “Company” or the “Group”)
Notice of results
Paris, France, and Manchester, UK – 23 September 2026 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its unaudited interim results for the six months ended 30 June 2026 on Wednesday 30 September 2026.
Investor webinar
An investor presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer will take place at 9.00am BST on Wednesday 30 September 2026.
The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation.
Investors can sign up for the webinar via:
https://www.investormeetcompany.com/novacyt-sa/register-investor
Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.
Contacts
Novacyt SA | https://novacyt.com/investors | |||
Lyn Rees, Chief Executive Officer | Via Walbrook PR | |||
Steve Gibson, Chief Financial Officer
|
| |||
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) | +44 (0)20 3470 0470 | |||
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) |
| |||
|
| |||
Singer Capital Markets (Joint Broker) | +44 (0) 20 7496 3000 | |||
Russell Cook / Graham Hertrich / James Fischer |
| |||
|
| |||
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit | +33 (1) 42 22 10 10[email protected] / [email protected] | |||
|
| |||
Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings / William Turner | +44 (0)20 7933 8780 or [email protected] +44 (0)7980 541 893 / +44 (0)7407 804 654 +44 (0)7407 020 470 | |||
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
Clinical | Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy testsPrecision Medicine: DPYD genotyping assayInfectious Diseases: Winterplex, multiplex winter respiratory PCR panel
|
Instrumentation | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: Ranger® Technology: automated DNA sample preparation and target enrichment technologygenesig q16 and q32 real-time quantitative PCR (qPCR) instruments
|
Research Use Only | Range of services for the life sciences industry: Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industryPharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) |
Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth (“ALNOV”).
For more information, please refer to the website: www.novacyt.com
Related Shares:
Novacyt